Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked higher than
78% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. RXII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RXII' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.76
RXII's Equity to Asset is ranked higher than
58% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RXII: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
RXII' s Equity to Asset Range Over the Past 10 Years
Min: -1.04  Med: 0.41 Max: 0.85
Current: 0.76
-1.04
0.85
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
70% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 3
Z-Score: -12.12
M-Score: -3.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -50452.63
RXII's Operating margin (%) is ranked lower than
97% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. RXII: -50452.63 )
Ranked among companies with meaningful Operating margin (%) only.
RXII' s Operating margin (%) Range Over the Past 10 Years
Min: -50452.63  Med: -12903.64 Max: -5250.38
Current: -50452.63
-50452.63
-5250.38
Net-margin (%) -50289.47
RXII's Net-margin (%) is ranked lower than
98% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. RXII: -50289.47 )
Ranked among companies with meaningful Net-margin (%) only.
RXII' s Net-margin (%) Range Over the Past 10 Years
Min: -50289.47  Med: -12836.36 Max: -5244.36
Current: -50289.47
-50289.47
-5244.36
ROE (%) -106.23
RXII's ROE (%) is ranked lower than
82% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. RXII: -106.23 )
Ranked among companies with meaningful ROE (%) only.
RXII' s ROE (%) Range Over the Past 10 Years
Min: -336.41  Med: -257.87 Max: -106.23
Current: -106.23
-336.41
-106.23
ROA (%) -89.29
RXII's ROA (%) is ranked lower than
85% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. RXII: -89.29 )
Ranked among companies with meaningful ROA (%) only.
RXII' s ROA (%) Range Over the Past 10 Years
Min: -603.25  Med: -203.85 Max: -72.95
Current: -89.29
-603.25
-72.95
ROC (Joel Greenblatt) (%) -6067.09
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. RXII: -6067.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RXII' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11172.8  Med: -4903.33 Max: -3597.18
Current: -6067.09
-11172.8
-3597.18
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

RXII Guru Trades in Q3 2015

Jim Simons 580,000 sh (+14.40%)
» More
Q4 2015

RXII Guru Trades in Q4 2015

Jim Simons 778,800 sh (+34.28%)
» More
Q1 2016

RXII Guru Trades in Q1 2016

Jim Simons 950,900 sh (-87.79%)
» More
Q2 2016

RXII Guru Trades in Q2 2016

Jim Simons 142,580 sh (+49.94%)
» More
» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:KTOV, NAS:JAGX, OTCPK:BIMUF, NAS:BVXV, OTCPK:TSSHF, OTCPK:PKTX, OTCPK:BRTX, NAS:XTLB, OTCPK:PRGB, OTCPK:MBXBF, NAS:EYEG, OTCPK:BLUSF, OTCPK:VBIO, NAS:CLRB, NAS:GNVC, NAS:RTTR, OTCPK:CRRTF, OTCPK:GRSO, NAS:OGXI, OTCPK:BPSR » details
Traded in other countries:44R1.Germany,
RXi Pharmaceuticals Corp is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology.

RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
P/B 2.48
RXII's P/B is ranked higher than
66% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. RXII: 2.48 )
Ranked among companies with meaningful P/B only.
RXII' s P/B Range Over the Past 10 Years
Min: 1.64  Med: 7.91 Max: 50.29
Current: 2.48
1.64
50.29
P/S 630.00
RXII's P/S is ranked lower than
95% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. RXII: 630.00 )
Ranked among companies with meaningful P/S only.
RXII' s P/S Range Over the Past 10 Years
Min: 64.67  Med: 200 Max: 1450
Current: 630
64.67
1450
Current Ratio 4.09
RXII's Current Ratio is ranked lower than
52% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. RXII: 4.09 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.74 Max: 11.98
Current: 4.09
0.48
11.98
Quick Ratio 4.09
RXII's Quick Ratio is ranked higher than
50% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. RXII: 4.09 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.74 Max: 11.98
Current: 4.09
0.48
11.98

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.86
RXII's Price/Net Cash is ranked higher than
78% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. RXII: 2.86 )
Ranked among companies with meaningful Price/Net Cash only.
RXII' s Price/Net Cash Range Over the Past 10 Years
Min: 2.32  Med: 7.7 Max: 17.2
Current: 2.86
2.32
17.2
Price/Net Current Asset Value 2.55
RXII's Price/Net Current Asset Value is ranked higher than
80% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. RXII: 2.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RXII' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.22  Med: 9.73 Max: 40.28
Current: 2.55
2.22
40.28
Price/Tangible Book 2.49
RXII's Price/Tangible Book is ranked higher than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. RXII: 2.49 )
Ranked among companies with meaningful Price/Tangible Book only.
RXII' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.18  Med: 8.96 Max: 35.79
Current: 2.49
2.18
35.79
Price/Median PS Value 3.15
RXII's Price/Median PS Value is ranked lower than
89% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. RXII: 3.15 )
Ranked among companies with meaningful Price/Median PS Value only.
RXII' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 0.99 Max: 6.75
Current: 3.15
0.37
6.75
Earnings Yield (Greenblatt) (%) -146.73
RXII's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. RXII: -146.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RXII' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1264.67  Med: 196.5 Max: 3918.01
Current: -146.73
-1264.67
3918.01

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -1.38
Beta1.14
Short Percentage of Float1.45%
52-Week Range $1.26 - 6.49
Shares Outstanding (Mil)6.56

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.39 -1.43 -0.75 -0.85
EPS w/o NRI ($) -1.39 -1.43 -0.75 -0.85
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RXII

Headlines

Articles On GuruFocus.com
Looking Ahead of Wall Street: RXI Pharmaceuticals, Titan Pharmaceuticals, Micron Technologies Mar 30 2015 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 

More From Other Websites
RXi Pharmaceuticals to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and... Sep 19 2016
ETF’s with exposure to RXi Pharmaceuticals Corp. : September 12, 2016 Sep 12 2016
RXi Pharmaceuticals to Present at the 4th Targeting Ocular Disorders Conference Sep 12 2016
RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum Sep 07 2016
RXi Pharmaceuticals to Present at the 9th Annual BioPharm America™ Conference Sep 06 2016
ETF’s with exposure to RXi Pharmaceuticals Corp. : September 1, 2016 Sep 01 2016
RXI PHARMACEUTICALS CORP Financials Aug 18 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2016
Q2 2016 Rxi Pharmaceuticals Corp Earnings Release - After Market Close Aug 11 2016
RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Aug 11 2016
RXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate... Aug 11 2016
RXi Pharmaceuticals to Webcast Second Quarter 2016 Financial Results on Thursday, August 11, 2016 Jul 28 2016
RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology Jul 21 2016
ETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016 Jul 20 2016
RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2016
RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 12 2016
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate... May 12 2016
RXi Pharmaceuticals Provides Strategic Update May 10 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Other Events May 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)